Duchenne Muscular Dystrophy (DMD) clinical trials
41 active trials name this condition (recorded in the registry as “Duchenne Muscular Dystrophy”) . Describe your situation to see which ones look like a fit.
Refine by biomarker
By location
- A Gene Transfer Therapy Study to Evaluate the Safety of and Expression From Delandistrogene Moxeparvovec (SRP-9001) in Participants With Duchenne Muscular Dystrophy (DMD) - Non-Ambulatory Cohort
- A Study of SGT-003 Gene Therapy in Ambulant Males With Duchenne Muscular Dystrophy (IMPACT DUCHENNE)
- Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
- PBGENE-DMD Phase 1/2a Safety and Preliminary Efficacy Study in Duchenne Muscular Dystrophy (FUNCTION-DMD)
- Phase 2 Study of SAT-3247 in Pediatric Ambulatory Patients
- A Study of SGT-003 Gene Therapy in Duchenne Muscular Dystrophy (INSPIRE DUCHENNE)
- Trial of Cell Based Therapy for DMD
- Open-label Study of WVE-N531 in Patients With Duchenne Muscular Dystrophy (FORWARD-53)
- Givinostat in Duchenne's Muscular Dystrophy Long-term Safety and Tolerability Study
- Modulation of SERCA2a of Intra-Myocytic Calcium Trafficking in Cardiomyopathy Secondary to Duchenne Muscular Dystrophy
- Vasodilator and Exercise Study for DMD (VASO-REx)
- Once Weekly Infant Corticosteroid Trial for DMD
- NS-089/NCNP-02-201 in Boys With Duchenne Muscular Dystrophy (DMD)
- A Study to Investigate the Safety and Biodistribution of a Single Intrathecal (IT) Injection of INS1201 in Ambulatory Males With Duchenne Muscular Dystrophy (DMD)
- A Study Evaluating the Real-World Experience of Givinostat in Patients With Duchenne Muscular Dystrophy
- The Baby Duchenne Study: Characterizing Developmental and Clinical Outcomes in the First Three Years in Children With Duchenne Muscular Dystrophy
- DMD Voice: Qualitative Interviews With Patients and Caregivers
- Establishing Walking-related Digital Biomarkers in Rare Childhood Onset Progressive Neuromuscular Disorders
- Registry Study to Observe Long-term Safety of Vamorolone (AGAMREE®) in Patients With Duchenne Muscular Dystrophy-SUMMIT
- Wearable Technology to Evaluate Hyperglycemia and HRV in DMD
- Wearable Technology to Evaluate Hyperglycemia and HRV in DMD - Longitudinal Aim
- Extracellular RNA Biomarkers of Duchenne Muscular Dystrophy
- Magnetic Resonance Imaging and Biomarkers for Muscular Dystrophy
- Modeling Mortality in Duchenne Muscular Dystrophy Cardiomyopathy: Identification of Surrogate Outcome Measures for DMD Drug Trials
- Duchenne Electronic Health Record Study
- Biomarker Development for Muscular Dystrophies
- The Duchenne Registry
- Molecular Analysis of Patients With Neuromuscular Disease
- FLOWER: Following Longitudinal Outcomes With Epidemiology for Rare Diseases
- Sodium/Glucose Cotransporter-2 Inhibitors (SGLT2i) Therapy in Duchenne Cardiomyopathy
- Urinary Titin Biomarker in DMD
- Glucagon-Like Peptide-1 Receptor Agonists to Attenuate Metabolic Risk in Individuals With Duchenne Muscular Dystrophy
- A Long-term Follow-up Study of Participants Who Received Delandistrogene Moxeparvovec (SRP-9001) in a Previous Clinical Study
- A Long-term Observational Study Evaluating Eteplirsen, Golodirsen, or Casimersen in Routine Clinical Practice
- Long Term Follow-up for RGX-202
- An Observational Study Comparing Delandistrogene Moxeparvovec (ELEVIDYS) With Standard of Care in Participants With Duchenne Muscular Dystrophy
- Parent and Infant Inter(X)Action Intervention (PIXI)
- AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)
- AFFINITY BEYOND: Anti-AAV8 Antibody Assessment Study of Males With DMD
- Early Check: Expanded Screening in Newborns
- Tissue Repository Providing Annotated Biospecimens for Approved Investigator-directed Biomedical Research Initiatives
Guides for people searching for a trial
- Why people get turned down — and what to do nextWhat eligibility criteria are for, what keeps people out, and where to go when the first door closes.
- How your biomarkers decide which trials you qualify forEGFR, HER2, BRAF, PD-L1 and the rest — what they are and why they increasingly gate access.
- How to search for a trial without losing your mindWhere to look, what to gather first, and how to read what you find.
- What Phase 1, 2 and 3 actually mean for youWhat each phase is testing, and how to weigh an early-phase trial against a later one.
- 10 questions to ask before you say yesTreatment, time, cost, safety and your rights. Worth bringing to a screening visit.
- You matched with a trial. What happens now?Phone screens, the screening visit, informed consent, and day one.
Showing active trials that list “Duchenne Muscular Dystrophy” as a condition. Eligibility shown on each trial is an estimate — the trial's study team makes the final decision.